Table 2. Univariate analysis of factors predictive of recurrence-free survival and overall survival.
| Factors | No. of patients | MDFST1 (95% CI) | P value | Factors | No. of patients | MOST2 (95% CI) | P value |
|---|---|---|---|---|---|---|---|
| Sex | 0.617 | Sex | 0.244 | ||||
| Male | 222 | 21.2 (16.5–33.0) | Male | 250 | 1791 (1423-NA) | ||
| Female | 100 | 19.2 (14.8–35.8) | Female | 120 | 1450 (899–2456) | ||
| Age (years) | 0.501 | Age (years) | 0.259 | ||||
| <68 | 228 | 19.2 (15.4–35.6) | <68 | 257 | 2456 (1560-NA) | ||
| ≥68 | 94 | 23.0 (18.4–36.7) | ≥68 | 113 | 1423 (887–1836) | ||
| Hepatitis B or C infection status | 0.510 | Hepatitis B or C infection status | 0.018 | ||||
| Negative | 126 | 19.2 (15.7–33.0) | Negative | 154 | 1135 (837–1694) | ||
| Positive | 188 | 21.6 (16.5–35.8) | Positive | 208 | 2456 (1624-NA) | ||
| Prothrombin time (sec.) | 0.474 | Prothrombin time (sec.) | 0.474 | ||||
| With normal range | 220 | 23.0 (19.2–35.8) | With normal range | 248 | 2116 (1560-NA) | ||
| Beyond normal range | 40 | 29.3 (18.3-NA) | Beyond normal range | 44 | NA(NA-NA) | ||
| Serum creatinine (mg/dL) | 0.564 | Serum creatinine (mg/dL) | 0.564 | ||||
| With normal range | 251 | 23.0 (19.2–33.9) | With normal range | 283 | 2131 (1622-NA) | ||
| Beyond normal range | 10 | 45.8 (11.8–NA) | Beyond normal range | 14 | 785 (419-NA) | ||
| Serum albumin (g/dL) | 0.622 | Serum albumin (g/dL) | 0.622 | ||||
| With normal range | 206 | 21.6 (18.3–35.6) | With normal range | 228 | 2116 (1560-NA) | ||
| Beyond normal range | 58 | 25.5 (15.9–71.1) | Beyond normal range | 70 | NA (837-NA) | ||
| Serum total bilirubin (mg/dL) | 0.145 | Serum total bilirubin (mg/dL) | 0.145 | ||||
| With normal range | 230 | 24.8 (19.4–36.7) | With normal range | 256 | 2131 (1624–3258) | ||
| Beyond normal range | 37 | 25.5 (14.8-NA) | Beyond normal range | 46 | 1622 (785-NA) | ||
| Child–Turcotte–Pugh classification | 0.153 | Child–Turcotte–Pugh classification | 0.153 | ||||
| A | 196 | 23.6 (18.6–36.7) | A | 220 | 2542 (1694-NA) | ||
| B or C | 19 | 23.9 (8.6–NA) | B or C | 22 | 887 (601-NA) | ||
| Alpha-fetoprotein (ng/mL) | 0.311 | Alpha-fetoprotein (ng/mL) | 0.258 | ||||
| <151,367 | 242 | 24.8 (19.2–35.8) | <151,367 | 275 | 2456 (1624-NA) | ||
| ≥151,367 | 5 | NA (13.1–NA) | ≥151,367 | 5 | NA (633-NA) | ||
| Extent of resection | <0.001 | Extent of resection | 0.024 | ||||
| Major | 169 | 35.6 (23.0–53.5) | Major | 198 | 2116 (1624-NA) | ||
| Minor | 152 | 13.6 (9.89–19.2) | Minor | 169 | 1147 (848-NA) | ||
| Residual tumor | 0.116 | Residual tumor | 0.168 | ||||
| No | 288 | 21.6 (18.2–33.0) | No | 324 | 1791 (1450–2542) | ||
| Yes | 15 | 15.6 (10.8–NA) | Yes | 18 | 1135 (837-NA) | ||
| Histologic grading by Edmondson and Steiner’s classification | 0.421 | Histologic grading by Edmondson and Steiner's classification | 0.654 | ||||
| I~II | 200 | 21.6 (18.4–30.0) | I~II | 230 | 1791 (1386–2542) | ||
| III~IV | 118 | 15.7 (11.7–42.0) | III~IV | 136 | 1622 (1149-NA) | ||
| Ishak fibrosis staging system | 0.472 | Ishak fibrosis staging system | 0.472 | ||||
| 0 | 60 | 23.9 (15.7–NA) | 0 | 74 | 2131 (931-NA) | ||
| 1–4 | 57 | 24.8 (16.5–36.7) | 1–4 | 61 | 1791 (1372-NA) | ||
| 5–6 | 73 | 18.3 (12.9–47.0) | 5–6 | 79 | NA (1685-NA) | ||
| Grade of liver inflammation | 0.369 | Grade of liver inflammation | 0.369 | ||||
| 0 | 104 | 23.9 (18.6–40.4) | 0 | 117 | 2131 (1624-NA) | ||
| 1–2 | 92 | 21.6 (17.6–47.0) | 1–2 | 101 | NA (1372-NA) | ||
| 3–4 | 15 | 18.3 (9.7–NA) | 3–4 | 17 | NA (359-NA) | ||
| American Joint Committee on Cancer TNM stage | <0.001 | American Joint Committee on Cancer TNM stage | <0.001 | ||||
| I~II | 225 | 30.0 (23.6–42.0) | I~II | 257 | 2456 (1694-NA) | ||
| III~IV | 76 | 9.6 (8.3–14.2) | III~IV | 89 | 660 (445–1791) | ||
| miR-99a-5p (RPM) | 0.081 | miR-99a-5p (RPM) | 0.003 | ||||
| ≥430.09 | 212 | 23.6 (19.7–33.9) | ≥430.09 | 236 | 1791 (1490-NA) | ||
| <430.09 | 110 | 12.9 (9.76–30.0) | <430.09 | 134 | 887 (633-NA) | ||
| 3miR-99a-5p (RPM) as a CV | 0.304 | 3miR-99a-5p (RPM) as a CV | <0.001 | ||||
| miR-100-5p (RPM) | <0.001 | miR-100-5p (RPM) | <0.001 | ||||
| ≥2821.42 | 245 | 27.2 (20.9–36.7) | ≥2821.42 | 277 | 2116 (1622–3258) | ||
| <2821.42 | 77 | 10.1 (7.85–15.7) | <2821.42 | 93 | 600 (431–1490) | ||
| 3miR-100-5p (RPM) as a CV | 0.220 | 3miR-100-5p (RPM) as a CV | 0.005 | ||||
| miR-148a-3p (RPM) | 0.015 | miR-148a-3p (RPM) | 0.009 | ||||
| ≥100929.3 | 144 | 25.5 (21.02–47.7) | ≥100929.3 | 162 | 2542 (1622-NA) | ||
| <100929.3 | 178 | 16.1 (13.1–25.3) | <100929.3 | 208 | 1386 (1147–1791) | ||
| 3miR-148a-3p (RPM) as a CV | 0.036 | 3miR-148a-3p (RPM) as a CV | 0.002 | ||||
Notes:
1Median disease-free survival time (month)
2Median overall survival time (day). Mismatches of patients numbers across the variables occurs due to some missing values.
3miRNA as a continuous variable (CV)
Abbreviations: CI (confidence interval), RPM (reads per million), TNM (Tumor Node Metastasis), NA (not available).